update: fda approves apalutamide (erleada) for metastatic castration-sensitive prostate cancer
Published 5 years ago • 6.5K plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
1:36
fda approves bayer's nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer
-
5:01
fda d.i.s.c.o.: a new drug approval for non-metastatic castration-resistant prostate cancer
-
0:54
apalutamide combination is well tolerated in metastatic castration-sensitive prostate cancer
-
34:48
apalutamide in metastatic castration-sensitive prostate cancer (mcspc): a case-based discussion
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
8:33
titan phase 3 trial with apalutamide in metastatic castration sensitive prostate cancer
-
2:50
live from asco: apalutamide for castration-sensitive prostate cancer
-
1:46
dr. agarwal on the qol with apalutamide in metastatic castration-sensitive prostate cancer
-
3:28
apalutamide and the titan clinical trial
-
1:17
fda approves first treatment for non-metastatic, castration-resistant prostate cancer
-
1:28
apalutamide plus adt leads to survival benefit in mcspc
-
6:44
hrqol among patients receiving apalutamide plus adt for metastatic castration-sensitive prostate can
-
0:53
“i have prostate cancer—how can adding apalutamide to standard treatment improve my outcomes?”
-
4:23
apalutamide for high-risk prostate cancer | learn about clinical trials
-
6:13
clinical implications of new data on apalutamide adt in castrate-sensitive prostate cancer
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
1:34
dr. chi on the titan trial results in metastatic castration-sensitive prostate cancer